Abbott Price Prediction: Where Will the Stock Be in 2027

Abbott is presented as a buy with a $125.10 price target, implying 24.24% upside from $100.69, despite shares trading near their 52-week low of $99.06 and below both key moving averages. Q4 2025 results were mixed, with adjusted EPS of $1.50 topping estimates but revenue of $11.459B missing consensus; management also guided to 6.5%-7.5% organic sales growth and $5.55-$5.80 adjusted EPS for 2026. Supportive factors include FreeStyle Libre momentum, a planned $21B Exact Sciences acquisition, and a 54-year dividend growth streak, while diagnostics and nutrition remain key risks.

Analysis

ABT looks like a classic “good company, bad tape” setup where the market is over-discounting near-term noise and underappreciating earnings durability. The second-order issue is that if organic growth re-accelerates into the new product cycle, the current de-rating can reverse quickly because the stock is already trading closer to a defensive multiple than a growth-augmented medtech platform. That makes this less about heroic re-rating assumptions and more about whether management can simply deliver the guided path and remove the overhang of uncertainty.

The biggest hidden catalyst is the upcoming print: with sentiment compressed and the stock near technical lows, a clean beat on volume/mix plus confident 2026 commentary could force systematic buyers back in. The market is also likely to care more about margin trajectory than headline revenue, since a large portion of the recent concern is really about whether lower-growth segments are masking operating leverage in the higher-quality franchise. If that leverage shows up, the stock can rerate faster than consensus models imply because defensive healthcare names typically bottom on forward estimates, not on reported results.

The acquisition is the real medium-term swing factor. In the near term, it may suppress multiple expansion because investors will anchor on execution risk and capital allocation, but over 12-24 months it can change the valuation framework if it creates a broader diagnostics growth story rather than just adding scale. The contrarian read is that the market may be over-focusing on legacy segment softness while missing that the core glucose franchise can partially offset cyclical or policy-driven weakness elsewhere, creating a more resilient earnings base than the chart suggests.

Key Decisions for Investors

• Buy ABT on pre-earnings weakness into the print over the next 48 hours; use a tight stop below the recent low because a clean beat/guidance raise could trigger a sharp multiple repair toward the low-$110s quickly.
• For event-driven upside, buy ABT call spreads expiring 4-8 weeks out to express a post-earnings re-rating while limiting downside if management only reiterates rather than raises guidance.
• Pair trade: long ABT / short a slower-growth defensive healthcare peer basket over 1-3 months, betting that quality growth plus dividend support will outperform in a market that rewards visible earnings durability.
• If EXAS closes as planned, consider a relative-value long ABT vs short EXAS on any acquisition-related volatility, since ABT should benefit from strategic diversification while the target likely loses takeover optionality and becomes event-risk sensitive.
• Take profits on any move above the prior 50-day average unless the company explicitly lifts full-year organic growth expectations; without that confirmation, the near-term trade is a squeeze, not a full secular rerate.